Abstract: This disclosure provides formulations of enzalutamide and their use for treating hyperproliferative disorders.

Abstract: This disclosure provides formulations of enzalutamide and their use for treating hyperproliferative disorders.

Abstract: This disclosure provides formulations of enzalutamide and their use for treating hyperproliferative disorders.

Abstract: Provided is a pharmaceutical composition for oral administration in which the solubility and/or dissolution properties of enzalutamide are improved and supersaturation is maintained. Also provided is a pharmaceutical composition for oral administration in which the oral absorbability of enzalutamide is improved. The pharmaceutical composition for oral administration comprises enzalutamide and polyvinyl alcohol.

Abstract: This disclosure provides formulations of enzalutamide and their use for treating hyperproliferative disorders.

Abstract: This disclosure provides formulations of enzalutamide and their use for treating hyperproliferative disorders.

Abstract: This disclosure provides formulations of enzalutamide and their use for treating hyperproliferative disorders.

Abstract: Provided herein is a tablet comprising, as a drug, N-(5-tert-butyl-isoxazol-3-yl)-N?-{4-[7-(2-morpholin-4-yl-ethoxy)imidazo[2,1-b][1,3]benzothiazol-2-yl]phenyl}urea or a pharmaceutically acceptable salt thereof, which is a medicament for treating acute myeloid leukemia (AML), the tablet characterized by comprising a composite of N-(5-tert-butyl-isoxazol-3-yl)-N?-{4-[7-(2-morpholin-4-yl-ethoxy)imidazo[2,1-b][1,3]benzothiazol-2-yl]phenyl}urea or a pharmaceutically acceptable salt thereof and hydroxypropyl-?-cyclodextrin in a ratio ranging from 1:8 to 1:20.

Abstract: This disclosure provides formulations of enzalutamide and their use for treating hyperproliferative disorders.

Abstract: Provided herein is a tablet comprising, as a drug, N-(5-tert-butyl-isoxazol-3-yl)-N?-{4-[7-(2-morpholin-4-yl-ethoxy)imidazo[2,1-b][1,3]benzothiazol-2-yl]phenyl}urea or a pharmaceutically acceptable salt thereof, which is a medicament for treating acute myeloid leukemia (AML), the tablet characterized by comprising a composite of N-(5-tert-butyl-isoxazol-3-yl)-N?-{4-[7-(2-morpholin-4-yl-ethoxy)imidazo[2,1-b][1,3]benzothiazol-2-yl]phenyl}urea or a pharmaceutically acceptable salt thereof and hydroxypropyl-?-cyclodextrin in a ratio ranging from 1:8 to 1:20.

Abstract: This disclosure provides formulations of enzalutamide and their use for treating hyperproliferative disorders.

Abstract: This disclosure provides formulations of enzalutamide and their use for treating hyperproliferative disorders.

Abstract: This disclosure provides formulations of enzalutamide and their use for treating hyperproliferative disorders.

Abstract: A pharmaceutical composition for oral administration, comprising 3-hydroxy-N1-(4-methoxybenzoyl)-N2-[4-(4-methyl-1,4-diazepan-1-yl)benzoyl]-1,2-phenylenediamine or a pharmaceutically acceptable salt thereof, and hydroxypropyl cellulose having a viscosity of approximately 6 mPa·S (inclusive) to approximately 150 mPa·S (exclusive) in a 2% aqueous solution at 20° C., or a viscosity of 75 mPa·S (inclusive) to 400 mPa·S (inclusive) in a 5% aqueous solution at 25° C., and a process of manufacturing the pharmaceutical composition for oral administration are disclosed.

Abstract: .epsilon. phase precipitates in the matrix having a composition of 0.07% or less carbon, 1 or less silicon, 1% or less manganese, 2.5 to 5% copper, 3 to 5.5% nickel, 14 to 17.5% chromium, 0.5% or less molybdenum, 0.15 to 0.45% niobium, by weight, and the balance composed substantially of iron, and comprising 6 to 30 vol % austenitic phase and the balance composed substantially of martensitic phase. In a method of producing a structural member in which first solution treatment is performed at 1010.degree. to 1050.degree. C. on a stainless steel having a composition described above and first aging treatment is performed at a temperature not lower than 520.degree. C. and not higher than 630.degree. C., second solution treatment is performed at 730.degree. to 840.degree. C., and then second aging treatment is performed at a temperature not lower than 520.degree. C. and not higher than 630.degree. C. or a structural member of any shape is fabricated by means of welding work before the second solution treatment.